NCT00844714View on ClinicalTrials.gov

Cardiovascular Risk Markers in Patients With Rheumatoid Arthritis: Effect of Rituximab Therapy

NACompletedINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2014

Conditions

Endothelial FunctionRheumatoid ArthritisInflammation

Interventions

DRUG

Rituxan

1000mg rituxan by intravenous infusion will be given on day 1 and day 15 of the study

Trial Locations (1)

94110

University of California, San Francisco, San Francisco

Sponsors

Collaborators (1)

Genentech, Inc.

All Listed Sponsors

collaborator

Genentech, Inc.

INDUSTRY

lead

University of California, San Francisco

OTHER